24 May 2013
Keywords: mixed, fortunes, companies, 1st, qtr, gilead, sciences
Article | 14 May 1998
Gilead Sciences said that once again revenues were derived from sales ofVistide (cidofovir injection), which the company markets independently
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 May 1998
© 2013 thepharmaletter.com